HCW Biologics seeks FDA pre-IND meeting for HCW11-018b T-cell engager program
HCWB•Clinical timeline remains on track
The program remains on track to start clinical trials in the first half of 2027.
FDA pre-IND meeting requested for HCW11-018b
HCW Biologics requested a Type B pre-IND meeting with the U.S. FDA for its investigational tetravalent T-cell engager HCW11-018b.
